Please ensure Javascript is enabled for purposes of website accessibility

Gilead Announces Q4 Financial Results, Misses EPS Target

By Mark Prvulovic - Feb 4, 2020 at 4:47PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech giant ended up falling a bit short of expectations.

Gilead Sciences (GILD 0.80%) announced its Q4 financial results on Tuesday afternoon. While the company ended up beating revenue expectations, Gilead's results were a little disappointing when it came to its earnings.

The biotech giant reported fourth-quarter revenues of $5.88 billion, which is a 1% increase from last year, while earnings-per-share fell to $1.30 per share in comparison to the $1.44 reported in Q4 2018, or a 9.8% decline. Although Gilead outperformed on the $5.7 billion revenue target analysts were expecting, the biotech giant fell significantly short of the $1.67 EPS target Wall Street was anticipating.

Multiple financial statements with a fountain pen and a pair of glasses.

Image source: Getty Images.

Gilead's HIV pill, Biktarvy, remains the company's top-selling product. The drug brought in $1.57 billion in revenue for the quarter, a substantial increase from the $578 million reported in Q4 2018. The company's second and third top-selling products, two other HIV treatments known as Genvoya and Truvada, saw revenues of $958 million and $768 million respectively. In comparison to last year, however, both drugs have seen their revenue figures fall off a bit, with Genvoya reporting a 20.6% decline in revenue while Truvada saw a 6.7% decline over the same period.

Further details

Some of the company's smaller drugs have also seen solid revenue growth as well. Yescarta, an immunotherapy treatment used to treat B-cell lymphoma (lymph node cancer), generated $122 million in sales during Q4 2019, a 50% increase from the $81 million reported a year ago. 

Gilead is also one of many biotech companies working to develop a possible coronavirus vaccine. The company's Ebola drug, remdesivir, has shown some promise in reducing symptoms in patients with the condition.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$63.08 (0.80%) $0.50

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
336%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.